Bretisilocin, also known as GM-2505 or 5-fluoro-N-methyl-N-ethyltryptamine, is a serotonergic psychedelic tryptamine analogue under development as a treatment for major depressive disorder. It's a 5-fluorinated derivative of methylethyltryptamine (MET) and an analogue of dimethyltryptamine (DMT). The administration route for Bretisilocin is intravenous infusion.
2022: First Description in Literature
In 2022, Bretisilocin was first described in the scientific literature.
June 2025: Phase 2 Clinical Trials
In June 2025, Bretisilocin is in phase 2 clinical trials for the treatment of major depressive disorder, and a phase 2a trial has been completed, with the efficacy and safety data released.
August 2025: Acquisition by AbbVie
In August 2025, AbbVie acquired Bretisilocin from Gilgamesh Pharmaceuticals for up to $1.2 billion.
Trending
3 hours ago Justin Wrobleski and Key Dodgers Activated as September Roster Expansion Begins
3 hours ago Bet365 Offers $365 Bonus Bets for MLB and College Football Week 1 Action
4 hours ago Jackson Holliday Hits Game-Tying Homer and Racks Up Three Hits in Strong Performance
13 days ago Jordan Walker and Joshua Baez Emerging as Promising Outfield Duo for St. Louis Cardinals
4 hours ago Keanu Reeves Halloween Costume and Potential Movie Reunion Updates
5 hours ago Jimmy Fallon and Roger Federer Attend 2026 US Open Tennis Tournament
Popular
Dolly Parton is a celebrated American singer-songwriter actress philanthropist and...
Michael Joseph Jackson the King of Pop was a highly...
Bernie Sanders is a prominent American politician and the senior...
Joe Biden served as the th President of the United...
John F Kennedy JFK was the th U S President...
Mark Zuckerberg is an American businessman and programmer best known...